Renin-angiotensin system blockade in older adults with chronic kidney disease

A review of the literature

Jessica Weiss, Micah L. Thorp, Ann M. O'Hare

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose of review: We have reviewed the literature examining the benefits and harms of renin-angiotensin system (RAS) blockade in older adults, using studies which included patients with chronic kidney disease (CKD) as well as those which included a broader patient population. Recent findings: We review the results of key trials which evaluate the impact of RAS blockade on renal outcomes, and those which address the impact of RAS blockade on more global outcomes (cardiovascular events and mortality). Many trials examining renal outcomes of RAS blockade excluded older patients or did not present age-stratified results, whereas trials which examined global outcomes often excluded patients with CKD. Most older patients with CKD have nonproteinuric nondiabetic CKD, thus differing from participants in trials which examined renal outcomes, which often included only patients with diabetes or proteinuria. Most studies did not address alternate outcomes which may carry greatest import for older patients, such as worsening comorbid illness or changes in functional status. Summary: The role of RAS inhibition for older patients with CKD remains unclear. Information on age-specific effects of RAS blockade on a range of different outcomes among older patients with CKD would improve our ability to assess the benefits and harms of RAS inhibition in this population.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume19
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Renin-Angiotensin System
Chronic Renal Insufficiency
Kidney
Proteinuria
Population
Mortality

Keywords

  • aging
  • angiotensin receptor blocker
  • angiotensin-converting enzyme inhibitor
  • chronic kidney disease
  • elderly

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Renin-angiotensin system blockade in older adults with chronic kidney disease : A review of the literature. / Weiss, Jessica; Thorp, Micah L.; O'Hare, Ann M.

In: Current Opinion in Nephrology and Hypertension, Vol. 19, No. 5, 09.2010, p. 413-419.

Research output: Contribution to journalArticle

@article{44168a1e97fa40399a582453a40f9bca,
title = "Renin-angiotensin system blockade in older adults with chronic kidney disease: A review of the literature",
abstract = "Purpose of review: We have reviewed the literature examining the benefits and harms of renin-angiotensin system (RAS) blockade in older adults, using studies which included patients with chronic kidney disease (CKD) as well as those which included a broader patient population. Recent findings: We review the results of key trials which evaluate the impact of RAS blockade on renal outcomes, and those which address the impact of RAS blockade on more global outcomes (cardiovascular events and mortality). Many trials examining renal outcomes of RAS blockade excluded older patients or did not present age-stratified results, whereas trials which examined global outcomes often excluded patients with CKD. Most older patients with CKD have nonproteinuric nondiabetic CKD, thus differing from participants in trials which examined renal outcomes, which often included only patients with diabetes or proteinuria. Most studies did not address alternate outcomes which may carry greatest import for older patients, such as worsening comorbid illness or changes in functional status. Summary: The role of RAS inhibition for older patients with CKD remains unclear. Information on age-specific effects of RAS blockade on a range of different outcomes among older patients with CKD would improve our ability to assess the benefits and harms of RAS inhibition in this population.",
keywords = "aging, angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, chronic kidney disease, elderly",
author = "Jessica Weiss and Thorp, {Micah L.} and O'Hare, {Ann M.}",
year = "2010",
month = "9",
doi = "10.1097/MNH.0b013e32833b8d6b",
language = "English (US)",
volume = "19",
pages = "413--419",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Renin-angiotensin system blockade in older adults with chronic kidney disease

T2 - A review of the literature

AU - Weiss, Jessica

AU - Thorp, Micah L.

AU - O'Hare, Ann M.

PY - 2010/9

Y1 - 2010/9

N2 - Purpose of review: We have reviewed the literature examining the benefits and harms of renin-angiotensin system (RAS) blockade in older adults, using studies which included patients with chronic kidney disease (CKD) as well as those which included a broader patient population. Recent findings: We review the results of key trials which evaluate the impact of RAS blockade on renal outcomes, and those which address the impact of RAS blockade on more global outcomes (cardiovascular events and mortality). Many trials examining renal outcomes of RAS blockade excluded older patients or did not present age-stratified results, whereas trials which examined global outcomes often excluded patients with CKD. Most older patients with CKD have nonproteinuric nondiabetic CKD, thus differing from participants in trials which examined renal outcomes, which often included only patients with diabetes or proteinuria. Most studies did not address alternate outcomes which may carry greatest import for older patients, such as worsening comorbid illness or changes in functional status. Summary: The role of RAS inhibition for older patients with CKD remains unclear. Information on age-specific effects of RAS blockade on a range of different outcomes among older patients with CKD would improve our ability to assess the benefits and harms of RAS inhibition in this population.

AB - Purpose of review: We have reviewed the literature examining the benefits and harms of renin-angiotensin system (RAS) blockade in older adults, using studies which included patients with chronic kidney disease (CKD) as well as those which included a broader patient population. Recent findings: We review the results of key trials which evaluate the impact of RAS blockade on renal outcomes, and those which address the impact of RAS blockade on more global outcomes (cardiovascular events and mortality). Many trials examining renal outcomes of RAS blockade excluded older patients or did not present age-stratified results, whereas trials which examined global outcomes often excluded patients with CKD. Most older patients with CKD have nonproteinuric nondiabetic CKD, thus differing from participants in trials which examined renal outcomes, which often included only patients with diabetes or proteinuria. Most studies did not address alternate outcomes which may carry greatest import for older patients, such as worsening comorbid illness or changes in functional status. Summary: The role of RAS inhibition for older patients with CKD remains unclear. Information on age-specific effects of RAS blockade on a range of different outcomes among older patients with CKD would improve our ability to assess the benefits and harms of RAS inhibition in this population.

KW - aging

KW - angiotensin receptor blocker

KW - angiotensin-converting enzyme inhibitor

KW - chronic kidney disease

KW - elderly

UR - http://www.scopus.com/inward/record.url?scp=77955928109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955928109&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e32833b8d6b

DO - 10.1097/MNH.0b013e32833b8d6b

M3 - Article

VL - 19

SP - 413

EP - 419

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 5

ER -